A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

被引：59

作者：

Chu Q.S.C. ^{[1
]}

Forouzesh B. ^{[2
]}

Syed S. ^{[2
]}

Mita M. ^{[2
]}

Schwartz G. ^{[3
]}

Copper J. ^{[2
]}

Curtright J. ^{[2
]}

Rowinsky E.K. ^{[2
]}

机构：

[1] Cross Cancer Institute, Edmonton, Alta. T6G 1Z2

[2] Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX

[3] Brooke Army Medical Center, Fort Sam Houston, TX

来源：

Investigational New Drugs | 2007年 / 25卷 / 4期

关键词：

COL-3; Metalloproteinase inhibitor; Soft tissue sarcoma;

D O I：

10.1007/s10637-006-9031-6

中图分类号：

学科分类号：

摘要：

This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and MMP-9, on a continuous oral schedule at a dose of 50 mg/m2 daily in patients with advanced and/or metastatic soft tissue sarcoma (STS). The principal endpoints were the rate of objective tumor regression and the proportion of patients who did not experience disease progression during the first 8 weeks of treatment. Other study objectives included an assessment of pharmacology of COL-3, time to progression (TTP), and overall survival. A Simon two-stage design with multinomial stopping rule was employed, with 15 patients enrolled during the first stage of the study. Although COL-3 was generally well-tolerated, there were no objective responses and 5(33%) patients experienced disease progression during the first 8 weeks of treatment, which exceeded the criteria established a priori with regard to pursuing further evaluations of COL-3 in STS. The median values for TTP and survival were 109 and 279 days, respectively. Based on these results, further studies of COL-3 on this administration schedule in patients with STS are not warranted. © 2007 Springer Science+Business Media, LLC.

引用

页码：359 / 367

页数：8

共 54 条

[1]

Brennan M.F., Alektiar K.M., Maki R.G., Soft tissue sarcoma, Cancer: Principles and Practice of Oncology, 6th Edn, (2001)

[2]

Bramwell V.H., Anderson D., Charette M.L., Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatoc soft tissue sarcoma, Cochrane Database Syst Rev, 3, (2003)

[3]

Von Mehren M., New therapeutic strategies for soft tissue sarcomas, Curr Treat Options Oncol, 4, pp. 441-451, (2003)

[4]

Hartmann J.T., Patel S., Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma, Drugs, 65, pp. 167-178, (2005)

[5]

Liotta L.A., Stetler-Stevenson W.G., Metalloproteinases and cancer, Semin Cancer Biol, 1, pp. 99-106, (1990)

[6]

Chambers A.F., Matrisian L., Changing view of the role of matrix metalloproteinases in metastases, J Natl Cancer Inst, 89, pp. 1260-1270, (1997)

[7]

Hidalgo M., Eckhardt S.G., Development of Matrix Metalloproteinase inhibitors in cancer therapy, J Natl Cancer Inst, 93, pp. 178-193, (2001)

[8]

Jeffrey J.J., Collagen and collagenase: Pregnancy and parturition, Semin Perinatol, 15, pp. 118-126, (1991)

[9]

Talhouk R., Bisselm M., Werb Z., Coordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution, J Cell Biol, 118, pp. 1271-1282, (1992)

[10]

Gonzales-Avila G., Iturria C., Vadillo F., Teran L., Selman M., Perez-Tamayo R., 72-kD (MMP-2) and 92 kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells, Pathobiology, 66, pp. 5-16, (1998)

← 1 2 3 4 5 6 →